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HCV genomic RNAer consideration as a principal target for newer HCV antivirals because its
destruction has the potential of eliminating the virus. These newer antivirals include deoxyribozymes (Dz),
which are small single-stranded DNA molecules that cleave homologous RNA targets. Using a liver cell model
containing functional genomic-length HCV-1b RNAwe tested whether 2′-O-methyl-modiﬁed Dz, designed to
recognize a highly-conserved RNA sequence located within the core-E1 coding region, could recognize and
cleave its target sequence in the structural context of a functional HCV RNA molecule. Dz858-4-OMe contains
four 2′-O-methyl nucleotide derivatives consecutively located on the distal ends of its two annealing arms.
Intracellular HCV RNA, core protein and HCV antigen expression were reduced by 63%, 87% and 84%,
respectively, when HCV RNA was challenged 6 h post-transfection with Dz858-4-OMe. The observed
reduction of intracellular HCV RNA and protein by Dz858-4-OMe suggests that it may constitute an attractive
HCV antiviral.
© 2008 Elsevier Inc. All rights reserved.Introduction
Chronic hepatitis caused by the hepatitis C virus (HCV) constitutes
a global health problem affecting a staggering 3% (170 million) of the
world's population (Timm and Roggendorf, 2007). Over time, the
chronic liver inﬂammation often leads to liver ﬁbrosis, hepatocellular
carcinoma or total liver failure (Chung, 2005; Leone and Rizzetto,
2005). In fact, HCV-induced liver cirrhosis and hepatocellular car-
cinoma represent the leading causes of liver transplantation in de-
veloped countries (Hoofnagle, 1997). According to current standard of
care, therapy consists of 24 to 48 weekly injections of interferon-α
combinedwith oral ribavirin (Mangia, 2007).While treatment efﬁcacy
varies with virus subtypes (Arase et al., 2004; Shiffman et al., 2007), on
average, this drug regimen achieves no more than a 54% to 61%
sustained virologic response (SVR) in chronically infected individuals
(Hughes and Shafran, 2006; Mangia, 2007). Low SVR is further
compounded by the ﬁnding that many patients undergoing this drug
regime experience serious side-effects, often leading to premature
discontinuation of therapy, virus breakout or virus rebound (Sookoian,
2003).
Although newer serine protease- or viral RNA polymerase-based
inhibitors have proven to be effective HCV antivirals, evidence sug-arch Centre, 3175 Côte Sainte-
514 345 4801.
e.qc.ca (C. Alﬁeri).
l rights reserved.gests that the virus becomes resistant to these inhibitors, the result
being a simple slowing of disease progression (Sheldon et al., 2007). A
different therapeutic approach whose mode of action attempts to
circumvent HCV mutant escape in order to directly eradicate intra-
cellular HCV genomic RNA may constitute a more appropriate alter-
native (Trepanier et al., 2006a).
A promising strategy currently under investigation to target pa-
thogenicmRNAs found in cancers (Fahmyet al., 2006), genetic diseases
(Yen et al., 1999) and in various viral infections (Chakraborti and
Banerjea, 2003; Lu et al., 2005; Takahashi et al., 2004; Zhao et al., 2003)
involves the use of small enzymatic DNA molecules called DNAzymes
or deoxyribozymes (Santoro and Joyce, 1998). These molecules are 30
to 40 nucleotides in length and consist of a catalytic core ﬂanked by
two RNA-target-speciﬁc annealing arms. Deoxyribozymes have sev-
eral advantages over other oligonucleotide-based therapeutics. These
include their autocatalytic ability to cleave cytoplasmic RNAs without
the requirement for RNAse H (Crooke, 2004). Further, deoxyribozymes
are less impacted by mutational changes in target RNAs or sequence
positional effects compared to antisense DNA or small inhibitory (si)
RNA (Schubert et al., 2004; Smith and Wu, 2003; Westerhout et al.,
2005; Wilson and Richardson, 2005).
In order for deoxyribozymes to bemost effective in recognizing the
myriad of HCV variants and quasispecies, their target sequence should
be highly conserved among the major virus genotypes, remain rela-
tively immutable to selective pressures and be accessible to the de-
oxyribozyme. Highly conserved and relatively stable RNA sequences
Fig. 1. Expression of HCV proteins in Huh-7 cells following transfection of synthetic,
genomic-length HCV RNA (A). Huh-7 cells either sham transfected (Mock), transfected
with HCV RNA (HCV RNA) or with HCV core protein eukaryotic expression plasmid
(pHCV-core). HCV protein expression was measured after 24 h of cell culture either by
immunoﬂuorescence (B) or after an equal amount of Huh-7 cellular protein was
resolved by SDS-PAGE and processed for immunoblot (C). HCV antigen ﬂuorescence or
HCV protein bands seen in immunoblots were detected using a pool of 10 HCV 1b-
positive human sera initially diluted to 1:50 and 1:500, respectively.
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principally within the 5′ and 3′UTRs, as well as the core protein and
NS5 coding domains (Thurner et al., 2004). It is hypothesized that sites
of high sequence conservation are required to maintain secondary and
tertiary RNA structures essential for virus RNA translation, replication
and stability (Tuplin et al., 2004).
In this study, we examined whether a highly conserved and
predicted ‘open’ RNA structure located near the core:E1 RNA coding
sequence boundary (Tuplin et al., 2004) was susceptible to deoxyr-
ibozyme cleavagewhen present in hepatocytes andwithin the context
of a functional genomic-length HCV RNA.
Results and discussion
HCV replication involves no DNA intermediate (Moradpour and
Blum, 2004). In theory, destruction of intracellular HCV RNA would
eliminate the virus from the cell. For this reason HCV RNA is gaining
greater consideration and importance as a principal target for newer
HCV antivirals (Romero-Lopez et al., 2006). Until recently many labo-
ratories tested various oligonucleotide-based platforms for in vitro- or
culture-based efﬁcacy using subgenomic RNA fragments (Oketani
et al., 1999; Smith et al., 2002; Trepanier et al., 2006b), however one
must acknowledge that recognition of subgenomic targets by a thera-
peutic oligonucleotide does not always faithfully translate into an
equivalent or sufﬁcient level of efﬁcacy when challenged with endo-
genous, full-length RNA (Smith et al., 2007; Swiatkowska et al., 2007).
Long RNAs, such as the HCV genome, are highly structured molecules
wherein up to 90% of putative cleavage sites were found to be in-
accessible upon testing (Schubert et al., 2004). Evenwith the advent of
the HCV 2b JFH-1strain/Huh-7 hepatoma replicative cell culture
model, investigators are still restricted in their drug testing (Wakita
et al., 2005). Currently no other natural HCV strain has been shown to
replicate as efﬁciently in culture without adaptive mutations (Pietsch-
mann et al., 2006) and, since these adaptivemutations appear to confer
unusual biological properties to the virus (Moriishi and Matsuura,
2007), it may be difﬁcult to assess their biological relevance when
testing antivirals (Kato et al., 2007). Based on a recent report wherein
the introduction of a synthetic copy of HCV JFH-1 RNA into Huh-7 cells
resulted in the translation and processing of the HCV polyprotein for
complete viral replication (Rouille et al., 2006), we examined whether
the introduction of an in vitro synthesized copy of theHCV genotype 1b
would similarly lead to proper processing and mimic viral replication
in Huh-7 cells. We chose to test the HCV 1b genotype given its pre-
valence in the worldwide population, increased virulence and poor
replication in culture (Zein, 2000; Kato et al., 2007). If successful, our
approach would mimic or exceed the level of viral RNA and protein
found in culture systems employing the JFH-1 viral strain. Following
RNA transfection, the synthetic genomic-length RNA was expected to
locate within the cytoplasm and fold into a functionally active form as
evidenced by its translation and the expression of properly processed
HCV polyprotein. Once veriﬁed, this HCV RNA could serve as a target,
comparable to endogenous HCV RNA and act as a rapid screening
methodwithwhich to test our library of deoxyribozymes. As shown in
Fig. 1 panels B and C, HCV antigens, including the mature form of the
virion core protein (Yasui et al., 1998), were seen in Huh-7 cells at 24 h
following HCV RNA transfection and cell culture, as detected with
pooled HCV 1b-positive human serum and measured by immuno-
ﬂuorescence or immunoblot. This indicated that the synthetic
genomic-length HCV 1b RNA properly located to the cytoplasm and
folded into a functionally active form capable of RNA translation ini-
tiation from the HCV IRES. Prior results from our laboratory indicated
that challenge of a subgenomic HCV RNA fragment encoding a com-
plete 5′UTR and core coding sequencewith the phosphorothioate (PS)-
linked anti-core deoxyribozyme (Dz858-2-PS) yielded a 32% reduction
in target RNA as measured by RT-qPCR (Trepanier et al., 2006b). In
order to develop a therapeutically useful molecule it was necessary toenhance its enzymatic activity through increased DNA:RNA annealing
and to eliminate or lessen PS-induced or CpG-induced toxicity by
employing 2′-O-methyl- (OMe-) modiﬁed nucleotides (Jason et al.,
2004; Judge et al., 2006; Kurreck, 2003). Newer Dz858 variants were
initially tested in an in vitro assay under physiologic conditions to
better gauge whether increased enzymatic activity would occur in
our cell culture model (Sood et al., 2007). Nonspeciﬁc RNA loss or
aberrant cleavage was monitored using a version of Dz858 that con-
tained an ablated catalytic site (mtDz858) (Santoro and Joyce, 1997).
Results from in vitro testing indicated that a Dz858 variant containing
four 2′-O-methyl (OMe) additions on each annealing arm (Dz858-4-
OMe) exhibited a four-fold higher level of enzymatic activity compared
to the previously reported Dz858-2-PS (2.1×105 kcat/KM for Dz858-4-
OMe versus 5.7×104 kcat/KM for Dz858-2-PS, Table 1) and exhibited an
enzymatic activity comparable to unmodiﬁed Dz858 (2.4×105 kcat/KM,
Table 1). Incubation of the RNA target with 1000-fold molar excess of
catalytically ablated Dz858 (mtDz858) revealed no detectable cleavage
activity (Fig. 2). Also, unlike earlier reports (Schubert et al., 2003), we
noted that deoxyribozymes having OMe-modiﬁed nucleotides within
the catalytic core (Dz858-4-OMe, 6-OMe core) did not increase clea-
vage activity; instead, we observed a signiﬁcant loss in enzyme activity
(Fig. 2 and Table 1).
Five different deoxyribozyme constructswere tested in theHCV cell
culture assay for their ability to reduce HCV RNA, namely 1) Dz858-4-
OMe, 2) Dz858-2-PS, 3) Dz2 which is an anti-core deoxyribozyme
(Oketani et al.,1999), 4) an OMe-modiﬁed variant of Dz2 (Dz2-4-OMe),
and 5) a Dz858 background control deoxyribozyme constructed as a
sense-mutant variant of Dz858 (mtDz858Sen). Deoxyribozymes were
transfected into Huh-7 cells at a ﬁxed concentration of 23 nM (Dz:HCV
RNA molar ratio of 75:1) 6 h after HCV RNA transfection to allow for
HCVRNAprocessing and to rule out possible cleavage of HCVRNAprior
to its entry into Huh-7 cells. Results from three independent
experiments indicated that Dz858-4-OMe reduced HCV RNA on
Table 1
Deoxyribozyme sequences and catalytic constants
Dz858 GAGCCAAGAGGAAGAGGCTAGCTACAACGAAGAAAAAGAGCAACC
Dz858-2-PS GSASGCCAAGAGGAAGAGGCTAGCTACAACGAAGAAAAAGAGCAAsCsC
Dz858-2-OMe MGMAGCCAAGAGGAAGAGGCTAGCTACAACGAAGAAAAAGAGCAAMCMC
Dz858-4-OMe MGMAMGMCCAAGAGGAAGAGGCTAGCTACAACGAAGAAAAAGAGCMAMAMCMC
Dz858-4-OMe, -6-OMe core MGMAMGMCCAAGAGGAAGAGMGCTAGMCMUACMAACMGMAAGAAAAAGAGCMAMAMCMC
Dz858-6-OMe core GAGCCAAGAGGAAGAGMGCTAGMCMUACMAACMGMAAGAAAAAGAGCAACC
mtDz858 GAGCCAAGAGGAAGAGGCGAGCTACAACGAAGAAAAAGAGCAACC
mtDz858Sen GGTTGCTCTTTTTCTGGCGAGCTACAACGATCTTCCTCTTGGCTC
Dz2 GSCSACGGTCTACGAGAGGCTAGCTACAACGACTCCCGGGGCACTSCSG
Dz2-4-OMe MGMCMAMCGGTCTACGAGAGGCTAGCTACAACGACTCCCGGGGCAMCMTMCMG
DNAzyme KM (mol/l) kcat (min−1) kcat/KM (mol/l)−1 min−1
Dz858 4.9×10−8 1.2×10−2 2.4×105
Dz858-2-PS 2.1×10−7 1.2×10−2 5.7×104
Dz858-2-OMe 8.6×10−8 9.4×10−3 1.1×105
Dz858-4-OMe 5.3×10−8 1.1×10−2 2.1×105
Dz858-4-OMe, 6-OMe core 5.8×10−8 4.9×10−3 8.5×104
Dz858-6-OMe core 5.8×10−8 5.4×10−3 9.3×104
Catalytic mutant, mt, underlined; S or PS, phosphorothioate; M or OMe, 2′-O-methyl; core, catalytic domain (sequence shown in bold).
KM and kcat values were determined using the Michaelis–Menten enzyme equation Y=(Vmax⁎X) /(KM+X)Y and the equation kcat=Vmax/St, respectively, where the Vmax was obtained
empirically, Y represents the % cleavage, X represents the deoxyribozyme concentration and St represents the original substrate concentration of 100 nM.
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mtDz858Sen activity (Fig. 3A), whereas Dz858-2-PS and Dz2 yielded
no marked change in HCV RNA reduction compared to mtDz858Sen.
Comparison of Dz858-4-OMe to its like-modiﬁed Dz2 variant (Dz2-4-
OMe) indicated that in-kind addition of OMe to a deoxyribozyme does
not ensure strong efﬁcacy, as Dz2-4-OMe appeared to reduce HCV RNA
by only 12.2%±5.4 SEM (Fig. 3A). The reduction of HCV RNA after
Dz858-4-OMe treatment was statistically signiﬁcant (p valueb0.004)
compared to Dz2, Dz2-4-OMe or Dz858-2-PS.
In conjunction with a reduction in HCV RNA, we also noted a
reduction in core protein and HCV antigen expression. Thirty hours
after Dz858-4-OMe addition, HCV core protein showed a reduction of
59% when detected by immunoblot using pooled HCV1b-positiveFig. 2. Schematic of Dz858 cleavage target and in vitro cleavage of HCV RNA by Dz858
variants. The plot of percent (%) RNA cleavage±SEM versus deoxyribozyme concentra-
tion was based on three independent experiments.human serum and normalizationwith cellular actin protein (Fig. 3B). It
is noteworthy that the 59% reductionwas obtained after subtraction of
mtDz858Sen background activity. Parallel experiments that measuredFig. 3. Reduction in intracellular HCV RNA (A), HCV core protein (B) and HCV antigen
reactivity (C) in Huh-7 cells following treatment with Dz858-4-OMe. Total cellular RNA
was harvested at 24 h post-transfection and plotted as percent HCV RNA reduction
±SEM from four independent experiments following total RNA normalization with β-
actin RNA (A). Cell protein or microscope slides containing Huh-7 cells were processed
36 h post-transfection for immunoblot (B) or HCV immunoﬂuorescence (C). HCV
antigen ﬂuorescence or HCV protein bands seen in immunoblots were detected using a
pool of 10 HCV 1b-positive human sera initially diluted to 1:50 and 1:500, respectively.
Fluorescence density±SEMwas plotted from three independent experiments and based
on N100 cells found in eight or more randomly chosen microscopic ﬁelds.
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treatment, immunostaining with pooled HCV1b-positive human
serum and digital quantitation of HCV antigen immunoﬂuorescence,
results indicated that Dz858-4-OMe reduced the HCV antigen signal
by 84% (following subtraction of background mock ﬂuorescence)
(Fig. 3C). By comparison, HCV antigen immunoﬂuorescence following
mtDz858Sen treatment did not differ signiﬁcantly from that of mock
treatment (Fig. 3C).
HCV replication involves no DNA intermediate and is entirely RNA
dependent (Moradpour and Blum, 2004). In theory, destruction of
intracellular HCV RNA should eliminate the virus from the cell.
Unfortunately the propensity of HCV to mutate rapidly has made HCV
RNA an elusive quarry. Poor annealing and removal of an intracellular
target RNA is generally linked to an inability of oligonucleotides to
access their counterpart sequences within the highly structured
environment of a large RNA molecule (Gallo et al., 2003). We have
tested and observed that an anti-core deoxyribozyme variant, Dz858-
4-OMe, recognized and reduced intracellular HCV RNA by 62.5%,
whereas the similarly modiﬁed anti-core deoxyribozyme Dz-2-4-OMe
reduced HCV RNA by only 12.2%. Other anti-core deoxyribozyme
variants tested failed to signiﬁcantly reduce HCV RNA levels (Fig. 3A).
The observed reduction of HCV RNA was further supported by our
observation that HCV core protein and HCV antigen expression were
reduced by 59% and 84%, respectively.
Unlike prior studies that tested antisense DNAs, ribozymes or de-
oxyribozymes with subgenomic HCV RNA targets (Romero-Lopez
et al., 2006) or chimeric viral replicons (Randall et al., 2003), our study
is the ﬁrst to report the reduction of genomic HCV 1b in hepatic cell
cultures following challenge with a deoxyribozyme-based antiviral.
Given that the amount of synthetic HCV RNA used in our cell culture
experiments (325 ng) equates to 6×1010 genomic copies per cell
culture, which would far exceed the number of expected HCV RNA
genome copies found in the HCV 2b JFH-1strain/Huh-7 replicative
cell culture model (Kato et al., 2007; Randall et al., 2007), our results
also testify to the robustness of our rapid-screen cell culture system
and the strength in efﬁcacy of Dz858-4-OMe. The concentration of
Dz858-4-OMe (23 nM) needed to achieve the marked reduction in
intracellular HCV RNA and HCV proteins was far lower than that
reported for the deoxyribozymes, ribozymes and antisense oligonu-
cleotides in other pathogenic cell models whose effective doses
ranged from 750 to 1000 nM (Beale et al., 2003; Oketani et al., 1999).
While the silencing efﬁciency of Dz858-4-OMe appears less than that
seen for siRNAs, the concentration of Dz858-4-OMe shown to reduce
HCV RNA compared favourably to siRNA whose effective dose ranged
from 25 nM to 100 nM (Beale et al., 2003; Randall et al., 2003; Seo
et al., 2003; Watanabe et al., 2007). Future studies which directly
compare the silencing efﬁciencies of siRNAs to their deoxyribozyme
counterparts for individual targets may allow for a better comparative
assessment of these two technologies.
Gene targeting using oligonucleotide-based strategies, including
deoxyribozymes, is gaining greater acceptance among medical re-
searchers as a valid antiviral platform by virtue of its precision tar-
geting of pivotal gene processes in the pathogenesis of disease. And
although deoxyribozymes offer several advantageous features beyond
those found for antisense or siRNA technologies, their acceptance has
been slow, due in part to an apparent limit in their reaction rates
compared to protein enzymes (Breaker et al., 2003) whose rates of
reaction are several orders of magnitude greater than those reported
for catalytic oligonucleotides. RNA cleavage by the various oligonu-
cleotide enzymes is believed to proceed through nucleophilic attack by
the 2′-oxygen of the ribose moiety on the phosphorus center of the
adjacent internucleotide linkage. Several distinct catalytic mechan-
isms have been proposed to explain how oligonucleotide-based en-
zymes, including deoxyribozymes, can accelerate this chemical
reaction. These include in-line nucleophilic attack, neutralization of
the negative charge on a non-bridging phosphate oxygen, deprotona-tion of the 2′-hydroxyl group and neutralization of the negative charge
on the 5′-oxygen atom (Breaker et al., 2003). However, unlike most
oligonucleotide enzymes that are limited to the in-line nucleophilic
attack or neutralization of negative charge on a non-bridging phos-
phate oxygen for their catalysis, deoxyribozymes such as Dz858,
display amore complex kinetic behaviour, suggesting that they can use
multiple catalytic mechanisms (Emilsson and Breaker, 2002). 2′-O-
methyl-modiﬁed nucleotides are reported to increase deoxyribozyme
activity through increased DNA:RNA afﬁnity. Our observation that
Dz858-OMe efﬁcacy differedmarkedly from an in-kind OMe-modiﬁed
anti-core deoxyribozyme (Dz2-4-OMe), coupled with the know-
ledge that Dz858-2-PS contains annealing sequences identical to
Dz858-4-OMe but displayed an inability to reduce intracellular HCV
RNA, suggested that OMe nucleotides must work in conjunction
with amenable nucleotide sequences to increase enzyme activity
(Lima et al., 1997).
In an attempt to develop an effective HCV antiviral, our laboratory
has designed a deoxyribozyme that signiﬁcantly reduced intracellular
HCV RNA and protein, thus positioning Dz858-4-OMe as a promising
HCV antiviral that may be added to and used in conjunction with the
current arsenal of HCV antivirals.
Materials and methods
Deoxyribozyme design and construction
HCV genotypes (www.hcvdb.org) were surveyed using database
mining of pan-HCV conserved secondary sequences (http://rna.tbi.
univie.ac.at/virus/) in conjunction with RNA secondary structure pre-
diction software (www.tbi.univie.ac.at/RNA/) and the m-fold compu-
ter program (www.bioinfo.rpi.edu/applications/mfold) (Zuker 2003)
for highly conserved, open-structured RNA sequences (Thurner et al.,
2004). An optimum RNA sequence located near the core:E1 RNA,
(nucleotides 844–8740) (Takamizawa et al., 1991) was found to have
deoxyribozyme cleavage potential. Deoxyribozymes for the site of
RNA cleavage (nucleotide 858) containing phosphorothioate (PS), 2′-
O-methyl (OMe) modiﬁcations, as well as Dz858 homologues with
ablated catalytic sites (mtDz858) or a sense strand to represent the
catalytically ablated version of Dz858 (mtDz858Sen), which serve as
control deoxyribozymes to distinguish in vitro or in vivo non-speciﬁc
cleavage and reduction in HCV RNA, respectively, were chemically
synthesized and puriﬁed by Na+ salt exchange (Integrated DNA Tech-
nologies, Coralville, IA) (Table 1). Na+ salt exchangewas recommended
by the manufacturer over HPLC puriﬁcation, as the latter puriﬁcation
method may introduce cytotoxic triethylammonium acetate into our
tissue cultures. Oligomers puriﬁed using Na+ salt exchange have pre-
viously been used in several cell culture systems to control gene ex-
pression (Dagle et al., 1990; Hu et al., 2003; Kalota and Opalinska,
2007).
In vitro synthesis of HCV RNA
A 976 base HCV type 1b RNA subgenomic fragment was used to
measure and screen the amount of in vitro cleavage by various Dz858
constructs. [32P]-radiolabeled HCV RNAwas generated from pGEM-7Zf-
HCV DNA template (kindly provided by Dr S. Mounir, Shire Phar-
maceuticals, Laval, QC) containing the bacteriophage T7 RNA poly-
merase promoter located adjacent to a HCV 1b 5′UTR and the core
protein coding sequence (Takamizawa et al.,1991). RNAwas synthesized
from 1 μg of PCR generated DNA template using the MegaScript T7
transcription kit (Ambion Inc., Austin, TX) and T7 RNA polymerase
(Ambion Inc.) in the presence or absence of [32P]UTP (20mCi/ml, 800 Ci/
mmol) (Amersham, Piscataway, NJ) (Trepanier et al., 2006b). Genomic-
length HCV RNAwas also synthesized by in vitro transcription from 1 μg
of pGEM-7Zf-HCV following its linearization with Xba I. Transcription
reactions proceeded at 37 °C for 6 h followed by DNA template removal
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and ethanol precipitation. Both the 976 base subgenomic fragment and
the full-length HCV RNA products were assayed for size and integrity
using 6% polyacrylamide gels containing 8Murea and Tris-borate buffer
or 0.8% formaldehyde-agarose gels, respectively (Sambrook et al.,1989).
KM and kcat determinations
[32P]-radiolabeled 976 base RNA substrate (100 nM) was incubated
for 1 h at 37 °C in 50 mM Tris–HCl buffer (pH 7.5) containing 10 mM
MgCl2 and increasing log10 concentrations of deoxyribozymes ranging
from 0.01 to 100 μM. Cleavage reactions were terminated by addition
of 95% formamide gel loading buffer, and cleavage products were
resolved by PAGE containing 8 M urea. Band intensity was quantiﬁed
using the SI PhosphorImager (Molecular Dynamics, Sunnyvale, CA).
The KM and kcat values for deoxyribozymes were determined using
the Michaelis–Menten enzyme equation Y=(Vmax⁎X)/ (KM+X) and the
equation kcat=Vmax/St, respectively, where the Vmax was obtained
empirically,Y represents the% cleavage,X represents thedeoxyribozyme
concentration and St represents the original substrate concentration of
100 nM (Prism 3.03 software, GraphPad Software Inc., San Diego, CA).
HCV RNA and protein expression following deoxyribozyme treatment
Huh-7 cells (kindly provided by Dr Tatsuo Takahashi, Health Science
Research Resources Bank, Japan) were seeded at 2.4×105 /well in 12-
well plates and cultured overnight in Dulbecco's Modiﬁed Eagles
Medium (DMEM) (Invitrogen) supplemented with 10% fetal bovine
serum (FBS) (Medicorp Inc., Montreal, Qc). They were then transfected
with 325 ng of synthetic full-length HCV 1b RNA using 3 μg Lipo-
fectamine 2000. After 6 h the cells were washed with PBS and
transfected with 23 nM of individual deoxyribozymes (molar ratio of
75:1). This concentration of deoxyribozyme had previously been shown
to yield a maximal difference in HCV RNA reduction when comparing
serial doses ofDz858-4-OMe tomtDz858Sen, asmeasured byRT-qPCR (J
Trepanier, unpublished).
HCV RNA concentrations were measured by RT-qPCR using
the HCV sense primer 5′-GGCGTGAACTATGCAACAGGGAAT-3′, 6′-
carboxyﬂuorescein, succinimidyl ester (FAM)-labeled probe 5′-
TTCCGCTTACGAAGTGCACAACGTGT-3′ and antisense primer 5′-
TGGAGCAGTCGTTCGTGACATGAT-3′ (Integrated DNA Technologies,
Coralville, IA) in conjunction with the QuantiTect Multiplex RT-PCR
Kit (Qiagen, Mississauga, ON) and Brilliant Multiplex QPCR master
mix containing carboxy-x-rhodamine succinimidyl ester (ROX)
reference dye (Stratagene Inc., La Jolla, CA). Primers and probes
were used at ﬁnal concentrations of 400 nM and 200 nM, respec-
tively. HCV cDNA was ampliﬁed and quantiﬁed using the Mx3000P
real-time PCR thermocycler (Stratagene Inc.) for 45 cycles, each con-
sisting of a 15-second incubation at 95 °C and a 1-minute annealing-
elongation step at 60 °C. Logarithmic concentrations of pHCV-UTR-
core plasmid ranging from 1 pg to 10 ng served as HCV PCR template
reference standards. Cellular HCV RNA concentrations were normal-
ized using β-actin which was also measured by RT-qPCR. β-actin
cDNA was ampliﬁed using β-actin sense primer 5′-CCTTCC-
TGGGCATGGAGTCCT-3′ and antisense primer 5′-GGAGCAATGATCTT-
GATCTTC-3′ in conjunction with the QuantiTect SYBR Green RT-PCR
Kit (Qiagen).
HCV core protein found in HCV RNA transfected Huh-7 cell extracts
was detected by immunoblot following incubationwith pooledHCV 1b-
positive human serum (1:500) that was pre-absorbed with Huh-7 cell
extracts. The pooled serum was obtained from 10 HCV 1b genotype-
positive, high viral load patients (kind gift from Dr H. Soudeyns, Sainte-
Justine Hospital Research Centre). We elected to use pooled human
serum in order to maximize assay sensitivity for HCV virion proteins
(Brochot et al., 2007). Following incubation with human serum, blots
were treated with biotinylated goat (Fab)2 anti-human IgG (1:8000),horseradish peroxidase (HRP)-streptavidin (1:6000, Sigma-Aldrich,
Oakville, ON) and chemiluminescence substrate (Sigma-Aldrich).
Overall HCV antigen expression was measured by immunoﬂuores-
cence. Huh-7 cells were seeded onto glass chamber slides (Nalgene
Nunc, Naperville, IL), transfectedwith full-lengthHCVRNA and treated
after 6 h with deoxyribozymes. They were cultured for an additional
30 h before processing for immunoﬂuorescence. In brief, methanol-
ﬁxed cells were incubated with pooled and absorbed HCV 1b-positive
human serum (1:50) followed by incubation with biotinylated goat
(Fab)2 anti-human IgG (1:600, Jackson ImmunoResearch Laboratories,
West Grove, PA) and 3 μg/ml dichlorotriazinyl amino ﬂuorescein
(DTAF)-conjugated streptavidin (Jackson ImmunoResearch). Digital
quantitation immunoblots of HCV core protein expression and HCV
antigen immunoﬂuorescence found in eight to 10 separatemicroscopic
ﬁelds were performed using ImageJ software (Rasband, W.S., US
National Institutes of Health, Bethesda, Maryland, USA).
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